Background: Although carotid artery stenting (CAS) has been proposed as an alternative to carotid endarterectomy in cerebral revascularization, restenosis remains an unsolved issue. Cilostazol is a unique antiplatelet drug that has vasodilatory effects and inhibits smooth muscle cell proliferation. We investigated whether cilostazol reduces restenosis after CAS.
Methods: A database of 113 consecutive CAS between April 2002 and December 2007
was assessed retrospectively. All patients received aspirin (100mg/day) and another antiplatelet drug such as cilostazol (200mg/day), ticlopidine (200mg/day), or clopidogrel (75mg/day) at least 3 days before CAS. Two antiplatelet drugs were continued for 2 to 3 months after CAS, and reduced to one thereafter. Patients were evaluated at 3 and 6 months and at 6-month intervals thereafter with duplex ultrasonography (US). Angiography was used to confirm when stenosis was suspected as greater than 50% with US.
Carotid artery stenting (CAS) is being used widely to treat severe carotid obstructive disease, and it is now accepted as a less invasive technique that provides an alternative for some patients, particularly those with significant comorbidities. [1] [2] [3] [4] [5] Although distal embolism decreased with use of the embolization protection device (EPD), up to 10% of patients develop > 50% stenosis as determined by angiography or carotid duplex ultrasound (US) scanning and this problem is not yet solved. 3, [6] [7] [8] In some patient subgroup, such as women and the elderly, it approaches 20%. 7 These series of studies placed aspirin, ticlopidine or clopidogrel as the current standard of antiplatelet drugs. Cilostazol, a cyclic adenosine monophosphate phosphodiesterase inhibitor, has multiple actions including vasodil ation and inhibition of platelet aggregation. [9] [10] [11] Cilostazol is widely used as an antiplatelet drug in Japan. Several small trials reported that cilostazol use after endovascular treatment with peripheral artery and coronary artery diseases has a low rate of in-stent restenosis. 12-22 However, it is not known whether a preventive effect of cilostazol on restenosis is similarly recognized after CAS. Accordingly, the present study was undertaken to determine whether cilostazol is effective in preventing restenosis after CAS compared to other antiplatelet drugs.
METHODS

Study design and patient sample.
A retrospective study was conducted of patients who had undergone CAS between April Standard retrograde access was achieved in the common femoral artery under local anesthesia with 1% lidocaine. An 8F vascular sheath was inserted. Heparin was administered to achieve an activated clotting time of over 300 seconds. An 8F guiding catheter was navigated into the common carotid artery. Carotid angiogram and intracranial injections were performed. A 0.018-inch guidewire system with EPD was then manipulated to cross the internal carotid lesion. For the patients with high-grade stenosis which was nearly occluded or with thrombosis, procedures were performed using the reversed-flow system. After the activation of the embolic system, a coaxial angioplasty balloon was used to predilate the carotid lesion if necessary. Next, a self-expanding carotid stent was deployed across the internal carotid stenosis. Post-dilatation was performed if necessary. On completion, ipsilateral cervical and intracranial carotid angiography was performed to assess technical success and to exclude distal cerebral embolization.
Patients were monitored in an intensive care unit overnight after the procedure, and were discharged 3 or 4 days after the procedure. Postprocedure clinical examination and duplex US scanning were performed before discharge, to confirm stent patency and position.
One antiplatelet drug was prescribed to be taken for life and another one to be terminated after 2 or 3 months. Aspirin was prescribed to be taken for life basically. In cases of the patients with peripheral artery disease or coronary artery disease, cilostazol and/or thienopyridine was added before carotid artery stenting. This combination of antiplatelet drugs was continued from the formula of the cardiovascular medicine. After CAS, this combination was continued for life.
Follow-up protocol and criteria for restenosis assessment.
All patients were followed at the hospital's outpatient clinic at 1, 3, 6, 9 and 12 months after the procedure and every 6 months thereafter. During these routine postoperative visits, the surgeon and independent neurologist examined each patient, and carotid duplex US scans were performed at 3 and 6 months and at 6-month intervals thereafter. The velocity criteria used to evaluate carotid artery stenosis were modifications of the Japanese Academy of Neurosonology Guidelines for Neurosonology and were validated in our hospital.
Peak systolic velocity greater than 150 cm/s correlated with greater than 50% stenosis. 24 Additionally, luminal reductions on grayscale images and color flow disturbances were further evaluated. In-stent restenosis, identified by US scanning, was further verified by carotid angiography, and stenosis was measured geometrically on the basis of the North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria. 25 When more than 50% restenosis was recognized, carotid angioplasty and possible stenting were subsequently performed.
Statistical analysis.
Clinical variables that may be associated with restenosis after CAS were analyzed. Data are shown as mean ± standard deviation (SD 
RESULTS
Thir ty-day and one-year outcome of car otid ar ter y stenting. 84.5%), AngioGuard XP (Cordis; n=7; 7.2%), and reversed-flow system (n=7; 7.2%).
Overall 30-day stroke, myocardial infarction, and death rate was 3.1% (n=3). Each of the three strokes was minor (two ipsilateral minor strokes and one contralateral stroke). in-stent restenosis and without in-stent restenosis, no significant difference was noted (Table 2) .
Two patients did not want re-treatment and were followed up with serial clinical evaluation and duplex US scanning at 3-month to 6-month intervals. Nine of eleven patients underwent endovascular repeat intervention; five of which were repeat balloon angioplasty with four being repeat angioplasty and secondary stenting. Technical successes were achieved in all patients, and the mean carotid artery stenosis decreased from 54.6% to 11% after reintervention. No procedural related complications were noted after in-stent restenosis intervention. All patients who underwent reintervention have remained rec urrence-free during follow-up periods (20.6 month median).
Post-CAS antiplatelet ther apy and in-stent r estenosis.
Antiplatelet drugs that were continued for 1-year after CAS are presented in  table  3 . The combinations of antiplatelet agents were as follows (aspirin n=28, ticlopidine n=3, clopidogrel n=10, cilostazol n=1, aspirin + ticlopidine n=23, aspirin + clopidogrel n=6, aspirin + cilostazol n=19, cilostazol + clopidogrel n=3, aspirin + ticlopidine + cilostazol n=1, aspirin + clopidogrel + cilostazol n=3).
No significant differences were noted in overall 30-day and 1-year stroke, myocardial infarction, and death among each drug group. Among the cilostazol (+) group, there were significantly fewer incidences of restenosis compared to patients without cilostazol (0% vs. 15.7%, p= .03). The restenosis rate was significantly higher in patients who took ticlopidine compared to patients without ticlopidine (25.9% vs.
5.7%, p= .01). Patient, lesion characteristics, and CAS technique did not differ
between the cilostazol (+) and cilostazol (-) groups. Use of additional drugs was similar between the groups, except that ticlopidine was used more frequently in the cilostazol (-) group than in the cilostazol (+) group.
DISCUSSION
The incidence of postprocedural in-stent restenosis ranges from 1% to 50% in published reports. In the study presented here, cilostazol was as effective as other antiplatelet drugs in preventing periprocedual and 1-year complications after CAS, as evidenced by the lack of any significant differences in vascular events observed at the 30-day and 1-year follow-ups. Furthermore, cilostazol showed more effectiveness in reducing restenosis after stent implantation than the other antiplatelet drugs. The inhibitory effect of cilostazol on restenosis may not be due to its antiplatelet effects but is possibly due to its direct inhibition of smooth muscle cell growth.
This study was a nonrandomized, retrospective at a single center trial,
and there were few numbers. A large-scale, prospective, multicenter study should be undertaken to verify these preliminary conclusion.
CONCLUSION
Cilostazol may have the potential to reduce the rate of restenosis after CAS due to its inhibitory effect on smooth muscle cell growth. 
